Literature DB >> 19822070

Psoriasis induced by infliximab in a patient suffering from Crohn's disease.

E Manni, P Barachini.   

Abstract

We describe the case of a 30-year-old female with no family history of psoriasis and suffering from Crohn's disease successfully treated with infliximab at the dosage of 5 mg/kg. On the 15th week from the start of therapy, the patient developed a palmoplantar pustular psoriasis, which spread to the arms, trunk and scalp with erythematosquamous plaques. Deeming the dermatitis onset due to the anti-TNF-alpha, we decided to discontinue infliximab, while starting with a topical therapy with emollients and corticosteroids and a systemic therapy with cyclosporine. These treatments achieved a clear improvement of psoriasis after 2 months and a complete regression of skin lesions after 4 months. Several cases have been reported of psoriasis induced by anti-TNF-alpha, which have shown to exert an effective therapeutic action on this disease. The pathogenic mechanism of such a paradoxical effect has not yet been explained, though a number of hypotheses were proposed, among which one of the most intriguing is that the rapid and strong blockade of TNF-alpha could result in an enhancement of INF-alpha activity with consequent induction of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822070     DOI: 10.1177/039463200902200331

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  3 in total

Review 1.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

Review 2.  Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Authors:  Isabelle Cleynen; Séverine Vermeire
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-03       Impact factor: 46.802

3.  Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn's disease.

Authors:  Hitoshi Amano; Reikei Matsuda; Tomohiko Shibata; Daisuke Takahashi; Shinichiro Suzuki
Journal:  Biologics       Date:  2017-05-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.